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Importance of the Project
Tuberous Sclerosis (TS) is an autosomal dominant, multisystem disorder that
affects 1 in 6000 live births. It is characterized by the development of hamartomas
(benign tumours) in various organs as well as various neurological disorders. TS
arises due to mutations in the tumour suppressor genes TSC2 and TSC1, which
encode Tuberin and Hamartin, respectively. Tuberin has been recently shown to
bind Cyclin B1, a mitotic cyclin, to control progression from G2 to mitosis of the cell
cycle. My project aims to characterize the cellular timing and localization of the
Tuberin and Cyclin B1 complex, using the bimolecular fluorescence
complementation (BiFC) system. Understanding this interaction would allow for a
greater understanding of the pathology of Tuberous Sclerosis, therefore
contributing to the development of effective treatments.
Existing State of Knowledge
Tuberous Sclerosis (TS) is an autosomal dominant, multisystem disorder that
affects 1 in 6000 live births. It is characterized by the development of hamartomas
(benign tumours) in various organs including skin, heart, lung, and brain, as well as
neurologic manifestations such as epilepsy, mental retardation, and autism. TS
arises due to mutations in the tumour suppressor genes TSC2 and TSC1. Mutations
in TSC2 are five times more common than mutations in TSC1, and patients with
mutations in TSC2 appear to be more severely affected. The protein products of
TSC2 and TSC1, Tuberin and Hamartin respectively, interact to form a heterodimer
complex, which regulates the cell cycle as well as other cellular processes such as
growth, and differentiation through the inhibition of mTOR. It is well known that the
Tuberin-Hamartin complex functions during G1/S to control these cellular
processes. However, it has recently been shown that Tuberin also functions during
the G2/M transition. Tuberin binds to Cyclin B1, a mitotic cyclin that partners with
Cdk1 (Cyclin-dependent kinase 1), to regulate mitotic onset.
Research Question
What is the timing and localization of the Tuberin-Cyclin B1 interaction, and
how does this interaction influence progression through the cell cycle?
Methodology
My research focuses on the construction of a set of bimolecular fluorescence
complementation (BiFC) vectors using molecular cloning techniques. The BiFC
vectors contain the gene of the protein to be studied (Tuberin or Cyclin B1)
conjugated with the amino (N) or carboxi (C) terminus of the yellow fluorescence
protein (YFP). When Tuberin and Cyclin B1 interact, a yellow fluorescent complex is
formed. Furthermore, I transfected mammalian HEK293 cells with these vectors and

analyzed the expression and interaction of Tuberin and Cyclin B1 in real time using
live cell fluorescence microscopy.
Your Findings
I have successfully created a set of mammalian BiFC vectors where the N- or
C-terminus of the YFP gene is conjugated to either the N- or C-terminus of the
Tuberin or Cyclin B1 genes. Furthermore, I have tested the expression of these
vectors in HEK293 cells and visualized the fluorescent complex formation using live
cell microscopy.
My results up to now have demonstrated that two of the four Tuberin-Cyclin
B1 vector combinations produce yellow fluorescence, while the other two
combinations exhibit no fluorescence. Knowing which combinations fluorescence
provides information about the 3D conformation of Tuberin, as its crystal structure
is currently unknown. Knowing which combinations fluoresce also allows us to
determine which vector combinations are most useful in terms of studying the
Tuberin-Cyclin B1 complex.
Moreover, when HEK293 cells are transfected with these two constructs, the
fluorescent cells arrest in G2 and do not appear to progress to mitosis. This is
significant because it confirms that the Tuberin-Cyclin B1 complex inhibits mitotic
onset. Additionally, literature suggests that bimolecular fluorescent complexes are
irreversible. However, my results suggest that the BiFC Tuberin-Cyclin B1 complex
is reversible, perhaps dependent upon concentration of transfected DNA.
Furthermore, immunofluorescence procedures together with the BiFC
system are being used to better visualize the cellular localization of the interaction
between Tuberin and Cyclin B1. Preliminary results suggest that Tuberin and Cyclin
B1 interact in a peri-nuclear fashion during the G2 phase of the cell cycle, before the
onset of mitosis.
Finally, the success of using the BiFC system to analyze the Tuberin-Cyclin B1
interaction suggests that this model would be advantageous in examining other
factors and pathways involved in the control of cell size and proliferation. The BiFC
system could be used to deduce the various mechanisms of not only Tuberous
Sclerosis, but many other cell reproduction diseases, such as cancer.

Abstract:
Tuberous Sclerosis (TS) is an autosomal dominant, multisystem disorder that
affects 1 in 6000 live births. It is characterized by the development of hamartomas
(benign tumours) in various organs as well as numerous neurologic manifestations
such as epilepsy, mental retardation, and autism. TS arises due to mutations in the
tumour suppressor genes TSC2 and TSC1. Mutations in TSC2 are five times more
common than mutations in TSC1, and patients with mutations in TSC2 appear to be
more severely affected. The protein products of TSC2 and TSC1, Tuberin and
Hamartin respectively, interact to form a heterodimer complex. This complex
regulates the cell cycle as well as other cellular processes such as growth and
differentiation through the inhibition of mTOR. It is well known that the Tuberin-

Hamartin complex functions during G1/S to control these cellular processes.
However, it has recently been shown that Tuberin also functions during the G2/M
transition. Tuberin binds to Cyclin B1, a mitotic cyclin that partners with Cdk1
(Cyclin-dependent kinase 1) to regulate mitotic onset. My project aims to
characterize the cellular timing and localization of the Tuberin-Cyclin B1
interaction, through the construction of a variety of mammalian expression vectors
using the bimolecular fluorescence complementation (BiFC) system. This unique
system employs the use of yellow fluorescence protein (YFP), in which the N- and Cterminus of this gene are conjugated to either the N- or C-terminus of the Tuberin or
Cyclin B1 genes. Through fluorescence microscopy, I have observed in real time two
of the four vector combinations interacting via the YFP fragments binding one
another to produce yellow fluorescence. Moreover, these fluorescent cells appear to
arrest in G2 and do not progress to mitosis, confirming that the Tuberin-Cyclin B1
complex does in fact inhibit mitotic onset. Furthermore, immunofluorescence
procedures suggest that Tuberin and Cyclin B1 interact in a peri-nuclear fashion
prior to the onset of mitosis.
Finally, the success of using the BiFC system to analyze the Tuberin-Cyclin B1
interaction will allow for a greater understanding of the pathology of Tuberous
Sclerosis and other growth related diseases, like cancer, contributing to the
development of effective treatments for these diseases.
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